Unknown

Dataset Information

0

Unorthodox Parenteral ?-Lactam and ?-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.

ABSTRACT: In India and China, indigenous drug manufacturers market arbitrarily combined parenteral ?-lactam and ?-lactamase inhibitors (BL-BLIs). In these fixed-dose combinations, sulbactam or tazobactam is indiscriminately combined with parenteral cephalosporins, with BLI doses kept in ratios similar to those for the approved BL-BLIs. Such combinations have been introduced into clinical practice without mandatory drug development studies involving pharmacokinetic/pharmacodynamic, safety, and efficacy assessments being undertaken. Such unorthodox combinations compromise clinical outcomes and also potentially contribute to resistance development.

SUBMITTER: Palwe S 

PROVIDER: S-EPMC7179625 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Unorthodox Parenteral β-Lactam and β-Lactamase Inhibitor Combinations: Flouting Antimicrobial Stewardship and Compromising Patient Care.

Palwe Snehal S   Veeraraghavan Balaji B   Periasamy Hariharan H   Khobragade Kshama K   Kharat Arun S AS  

Antimicrobial agents and chemotherapy 20200421 5

In India and China, indigenous drug manufacturers market arbitrarily combined parenteral β-lactam and β-lactamase inhibitors (BL-BLIs). In these fixed-dose combinations, sulbactam or tazobactam is indiscriminately combined with parenteral cephalosporins, with BLI doses kept in ratios similar to those for the approved BL-BLIs. Such combinations have been introduced into clinical practice without mandatory drug development studies involving pharmacokinetic/pharmacodynamic, safety, and efficacy ass  ...[more]

Similar Datasets

Unknown ?-lactam/?-lactamase inhibitor combinations: an update.
| S-EPMC6151480 | biostudies-literature
Unknown Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".
| S-EPMC7609624 | biostudies-literature
Unknown Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
| S-EPMC8139903 | biostudies-literature
Unknown In Vitro Activities of ?-Lactam-?-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens.
| S-EPMC7187596 | biostudies-literature
Unknown Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis ?-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of ?-lactam-?-lactamase inhibitor combinations.
| S-EPMC3837893 | biostudies-literature
Unknown A Multinational, Preregistered Cohort Study of ?-Lactam/?-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae.
| S-EPMC4914653 | biostudies-literature
Unknown Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined ?-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of ?-Lactam-?-Lactamase Inhibitor Combinations.
| S-EPMC4808171 | biostudies-literature
Unknown Coproduction of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae: Implications for Newer ?-Lactam-?-Lactamase Inhibitor Combinations.
| S-EPMC4767958 | biostudies-literature
Unknown The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.
| S-EPMC2144209 | biostudies-other
Unknown Efficacy of ?-Lactam/?-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
| S-EPMC5527609 | biostudies-literature